Juniper Pharmaceuticals Company Profile (NASDAQ:JNP)

About Juniper Pharmaceuticals (NASDAQ:JNP)

Juniper Pharmaceuticals logoJuniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women's health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women's health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:JNP
  • CUSIP: N/A
  • Web:
  • Market Cap: $45.54 million
  • Outstanding Shares: 10,843,000
Average Prices:
  • 50 Day Moving Avg: $4.22
  • 200 Day Moving Avg: $4.93
  • 52 Week Range: $3.65 - $8.00
  • Trailing P/E Ratio: 7.43
  • Foreward P/E Ratio: -9.13
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $55.34 million
  • Price / Sales: 0.82
  • Book Value: $3.59 per share
  • Price / Book: 1.17
  • EBIDTA: $7.46 million
  • Net Margins: -7.44%
  • Return on Equity: -9.68%
  • Return on Assets: -6.47%
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 1.73%
  • Quick Ratio: 1.42%
  • Average Volume: 49,034 shs.
  • Beta: 0.25
  • Short Ratio: 2.62

Frequently Asked Questions for Juniper Pharmaceuticals (NASDAQ:JNP)

What is Juniper Pharmaceuticals' stock symbol?

Juniper Pharmaceuticals trades on the NASDAQ under the ticker symbol "JNP."

How were Juniper Pharmaceuticals' earnings last quarter?

Juniper Pharmaceuticals Inc (NASDAQ:JNP) released its earnings results on Thursday, May, 4th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The firm had revenue of $11.25 million for the quarter, compared to the consensus estimate of $11.27 million. Juniper Pharmaceuticals had a negative return on equity of 9.68% and a negative net margin of 7.44%. View Juniper Pharmaceuticals' Earnings History.

Where is Juniper Pharmaceuticals' stock going? Where will Juniper Pharmaceuticals' stock price be in 2017?

3 brokers have issued 12-month price targets for Juniper Pharmaceuticals' shares. Their forecasts range from $6.75 to $12.00. On average, they anticipate Juniper Pharmaceuticals' stock price to reach $9.38 in the next twelve months. View Analyst Ratings for Juniper Pharmaceuticals.

Are investors shorting Juniper Pharmaceuticals?

Juniper Pharmaceuticals saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 132,588 shares, a drop of 18.7% from the March 31st total of 163,022 shares. Based on an average trading volume of 37,083 shares, the short-interest ratio is currently 3.6 days.

Who are some of Juniper Pharmaceuticals' key competitors?

Who are Juniper Pharmaceuticals' key executives?

Juniper Pharmaceuticals' management team includes the folowing people:

  • James A. Geraghty, Independence Chairman of the Board
  • Jeffrey E. Young, Chief Financial Officer, Vice President - Finance, Treasurer, Secretary
  • Nikin Patel, Chief Operating Officer, Director
  • Bridget A. Martell, Chief Medical Officer
  • Frank C. Condella Jr., Non-Executive Director
  • Frank Murdoch Armstrong, Independent Director
  • Cristina Csimma Pharm.D., Independent Director
  • Mary Ann Gray Ph.D., Independent Director
  • Ann Merrifield, Independent Director

Who owns Juniper Pharmaceuticals stock?

Juniper Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.16%), Heartland Advisors Inc. (3.69%), Renaissance Technologies LLC (2.85%), Wells Fargo & Company MN (1.16%), Algert Global LLC (1.00%) and AWM Investment Company Inc. (0.92%). Company insiders that own Juniper Pharmaceuticals stock include Alicia Secor, C Ann Merrifield, Frank Condella Jr, Frank M Armstrong, George Elston, James A Geraghty and Nikin Patel. View Institutional Ownership Trends for Juniper Pharmaceuticals.

Who sold Juniper Pharmaceuticals stock? Who is selling Juniper Pharmaceuticals stock?

Juniper Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Gabelli Funds LLC and Spark Investment Management LLC. View Insider Buying and Selling for Juniper Pharmaceuticals.

Who bought Juniper Pharmaceuticals stock? Who is buying Juniper Pharmaceuticals stock?

Juniper Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Renaissance Technologies LLC, Algert Global LLC, KCG Holdings Inc., Goldman Sachs Group Inc., Morgan Stanley, TFS Capital LLC and Acadian Asset Management LLC. Company insiders that have bought Juniper Pharmaceuticals stock in the last two years include Alicia Secor, C Ann Merrifield, Frank Condella Jr, Frank M Armstrong, George Elston, James A Geraghty and Nikin Patel. View Insider Buying and Selling for Juniper Pharmaceuticals.

How do I buy Juniper Pharmaceuticals stock?

Shares of Juniper Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juniper Pharmaceuticals' stock price today?

One share of Juniper Pharmaceuticals stock can currently be purchased for approximately $4.20.

MarketBeat Community Rating for Juniper Pharmaceuticals (NASDAQ JNP)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Juniper Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Juniper Pharmaceuticals (NASDAQ:JNP) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $9.38 (123.21% upside)

Analysts' Ratings History for Juniper Pharmaceuticals (NASDAQ:JNP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017HC WainwrightReiterated RatingHoldN/AView Rating Details
5/6/2017Roth CapitalSet Price TargetBuy$12.00LowView Rating Details
8/18/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Juniper Pharmaceuticals (NASDAQ:JNP)
Earnings by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Earnings History by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.09)($0.13)$11.27 million$11.25 millionViewListenView Earnings Details
3/7/2017Q4 2016$0.45$0.88$15.33 million$20.93 millionViewListenView Earnings Details
11/15/2016Q3 2016($0.15)$0.02$10.58 million$11.56 millionViewN/AView Earnings Details
8/4/2016Q216($0.08)($0.16)$9.49 million$11.89 millionViewN/AView Earnings Details
5/4/2016Q116($0.08)$0.03$9.13 million$12.10 millionViewN/AView Earnings Details
3/10/2016Q415($0.02)($0.19)$7.89 million$7.60 millionViewN/AView Earnings Details
11/10/2015Q315($0.05)$0.09$7.10 million$11.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.02)($0.03)$8.35 million$10.20 millionViewN/AView Earnings Details
5/6/2015Q115$0.04$0.07$7.80 million$8.30 millionViewN/AView Earnings Details
3/18/2015Q414$0.07($0.05)$7.93 million$7.30 millionViewN/AView Earnings Details
10/28/2014Q314$0.12$0.34$9.74 million$11.50 millionViewN/AView Earnings Details
7/31/2014Q2$0.11$0.01$6.86 millionViewN/AView Earnings Details
3/5/2014Q413$0.08$7.10 million$7.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.16$0.20$6.75 million$7.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.02$0.03$6.50 million$7.02 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.03$0.01$6.50 million$6.30 millionViewN/AView Earnings Details
3/14/2013Q4 2012$0.02$0.03$7.60 million$6.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Juniper Pharmaceuticals (NASDAQ:JNP)
Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.46 EPS


Dividend History for Juniper Pharmaceuticals (NASDAQ:JNP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Juniper Pharmaceuticals (NASDAQ:JNP)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 33.12%
Insider Trades by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Institutional Ownership by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Insider Trades by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2017James A GeraghtyDirectorBuy2,000$4.82$9,640.00View SEC Filing  
9/13/2016James A GeraghtyDirectorBuy2,000$5.97$11,940.00View SEC Filing  
8/31/2016George ElstonCFOBuy1,000$5.50$5,500.00View SEC Filing  
8/26/2016C Ann MerrifieldDirectorBuy2,000$5.63$11,260.00View SEC Filing  
8/25/2016Alicia SecorInsiderBuy5,000$5.75$28,750.00View SEC Filing  
8/23/2016James A GeraghtyDirectorBuy7,000$5.96$41,720.00View SEC Filing  
12/4/2015C Ann MerrifieldDirectorBuy1,600$12.14$19,424.00View SEC Filing  
11/19/2015Nikin PatelCOOBuy5,000$11.82$59,100.00View SEC Filing  
11/18/2015Frank Condella JrCEOBuy5,000$11.68$58,400.00View SEC Filing  
8/14/2015C Ann MerrifieldDirectorBuy3,000$9.90$29,700.00View SEC Filing  
6/15/2015Frank M ArmstrongDirectorBuy1,255$7.95$9,977.25View SEC Filing  
6/9/2015Nikin PatelCOOBuy13,500$7.52$101,520.00View SEC Filing  
5/8/2015Frank Condella JrCEOBuy10,000$7.36$73,600.00View SEC Filing  
11/20/2014Donald H HunterDirectorBuy1,000$5.98$5,980.00View SEC Filing  
8/13/2014Frank Condella JrCEOBuy10,000$5.98$59,800.00View SEC Filing  
5/5/2014Frank Condella JrCEOBuy10,000$6.65$66,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Juniper Pharmaceuticals (NASDAQ:JNP)
Latest Headlines for Juniper Pharmaceuticals (NASDAQ:JNP)
DateHeadline logoJuniper Pharmaceuticals Inc (JNP) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS - May 8 at 6:04 PM logoEdited Transcript of JNP earnings conference call or presentation 4-May-17 12:30pm GMT - May 8 at 5:44 PM logoHC Wainwright Reaffirms Hold Rating for Juniper Pharmaceuticals Inc (JNP) - May 5 at 5:38 PM logoJuniper Pharmaceuticals posts 1Q loss - May 4 at 12:16 PM logo$11.27 Million in Sales Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter - May 4 at 1:37 AM logoJuniper Pharmaceuticals Inc (JNP) Expected to Post Earnings of -$0.09 Per Share - May 4 at 1:36 AM logoJuniper Pharmaceuticals Inc (JNP) Receives Average Rating of "Hold" from Analysts - May 3 at 12:58 AM logoJuniper Pharmaceuticals (JNP) Receiving Somewhat Critical News Coverage, Analysis Shows - May 1 at 4:48 PM logoJuniper Pharmaceuticals Inc (JNP) Short Interest Down 18.7% in April - April 30 at 1:03 PM logoJuniper Pharmaceuticals Inc (JNP) Expected to Post Quarterly Sales of $11.27 Million - April 30 at 10:14 AM logo Analysts Expect Juniper Pharmaceuticals Inc (JNP) to Announce -$0.09 Earnings Per Share - April 28 at 10:02 AM logoJuniper Pharmaceuticals to Report First Quarter 2017 Results on May 4, 2017 - April 28 at 9:47 AM logoJuniper Pharmaceuticals (JNP) Receives Media Impact Rating of -0.25 - April 27 at 3:06 PM logoJuniper Pharmaceuticals (JNP) Receives Coverage Optimism Score of -0.06 - April 21 at 9:20 PM logoJuniper Pharmaceuticals (JNP) Earning Favorable News Coverage, Analysis Finds - April 17 at 9:09 AM logoJuniper Pharmaceuticals Inc (JNP) Upgraded by TheStreet to "C" - April 17 at 12:52 AM logoKrensavage Asset Management Urges Juniper Pharmaceuticals to Consider Sale of Company - April 12 at 8:51 AM logoETFs with exposure to Juniper Pharmaceuticals, Inc. : April 10, 2017 - April 10 at 5:45 PM logoZacks: Analysts Anticipate Juniper Pharmaceuticals Inc (JNP) Will Announce Quarterly Sales of $11.27 Million - April 8 at 8:00 AM logoJuniper Pharmaceuticals Inc (JNP) Expected to Announce Earnings of -$0.09 Per Share - April 7 at 12:13 AM logoJuniper Pharmaceuticals Inc (JNP) Receives Consensus Recommendation of "Hold" from Brokerages - April 5 at 4:54 PM logoJuniper Pharmaceuticals Recognized for Board Diversity at Get Konnected! 9th Anniversary Event - March 29 at 10:25 AM logoJuniper Pharmaceuticals Inc (JNP) Receives Consensus Recommendation of “Hold” from Analysts - March 10 at 2:45 PM logoJuniper Pharmaceuticals Inc (JNP) Issues Quarterly Earnings Results - March 8 at 2:21 PM logoJuniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results - March 7 at 10:51 AM logoJUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a - March 7 at 10:51 AM logoQ4 2016 Juniper Pharmaceuticals Inc Earnings Release - Before Market Open - March 7 at 10:51 AM logoJuniper Pharmaceuticals to Present at ROTH Conference on March 14, 2017 - March 6 at 5:38 PM logoJuniper Pharmaceuticals to Report Fourth Quarter and Year-End 2016 Results on March 7, 2017 - March 1 at 11:30 AM logoLatest version of Dodd-Frank reversal bill would exempt a third of public companies from giving auditor warning - February 16 at 5:45 PM logoJuniper Pharmaceuticals Presents Poster at SMFM 2017 on Current Practice Among U.S. Obstetricians to Screen, Define, and Treat a Short Cervix to Prevent Preterm Birth - January 26 at 7:49 PM logoJuniper Pharmaceuticals Unveils Strategic and Product Development Objectives for 2017 - Yahoo Finance - January 7 at 4:46 AM logoBRIEF-Juniper Pharma will focus on IND-enabling activities for JNP-0201 - January 6 at 6:46 PM logo8:01 am Juniper Pharma announced plans for 2017 that are expected to enable the Company to submit Investigational New Drug applications for its hormone-delivery intravaginal ring candidates in the first half of 2018 - January 6 at 6:45 PM logoBRIEF-Juniper Pharmaceuticals prototype formulation development for JNP-0301 is underway - January 5 at 7:22 PM logoJUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, - December 23 at 6:19 PM logoJuniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer - PR Newswire (press release) - December 21 at 8:20 AM logo8:01 am Juniper Pharma appoints Jeffrey Young to succeed George Elston as CFO effective Jan 1, 2017 - December 20 at 11:38 AM logoJUNIPER PHARMACEUTICALS INC Financials - November 19 at 5:52 PM



Juniper Pharmaceuticals (JNP) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff